NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

腫瘤特別抗原的全球市場

Global Tumor-specific Antigen Market

出版商 BCC Research 商品編碼 845211
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
腫瘤特別抗原的全球市場 Global Tumor-specific Antigen Market
出版日期: 2019年05月14日內容資訊: 英文 140 Pages
簡介

全球腫瘤特別抗原市場,預計從2018年的18億美元到2023年擴大到24億美元,其間預計為6.2%的年複合成長率。

本報告提供全球腫瘤特別抗原市場調查,市場概要,市場趨勢的分析與預測,各市場區隔、各地區的分析與預測,癌症研究的政府法規架構、政策、資金舉措,及主要企業的簡介等系統性資訊。

第1章 簡介

第2章 摘要、亮點

第3章 市場、技術背景

  • 市場概要
  • 市場潛在性
  • 投資分析
  • 法律規範
  • 促進產業成長因素

第4章 腫瘤特別抗原市場:各分類

  • 腫瘤胎兒
  • 腫瘤病毒
  • 過表達/積累
  • CT9/CT10
  • 突然變異
  • 系統限制抗原
  • 個體遺傳型
  • 其他

第5章 腫瘤特別抗原市場:各來源

  • 編碼領域
  • 非編碼領域

第6章 腫瘤特別抗原市場:各用途

  • 診斷
  • 藥物研發、開發
  • 治療
  • 風險評估
  • 預後
  • 臨床、基礎研究

第7章 腫瘤特別抗原市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第8章 腫瘤特別抗原市場產業結構

  • 產業結構
  • 市場上革新
  • 競爭分析

第9章 企業簡介

  • ABCAM PLC
  • AGILENT TECHNOLOGIES INC.
  • AIVITA BIOMEDICAL
  • BBI GROUP
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES INC.
  • BRIGHTPATH BIOTHERAPEUTICS
  • CARIS LIFE SCIENCES INC.
  • CISBIO BIOASSAYS
  • CREATIVE DIAGNOSTICS
  • ELI LILLY AND CO.
  • ENZO BIOCHEM INC.
  • EXTERNAUTICS
  • F. HOFFMANN-LA ROCHE LTD.
  • GO THERAPEUTICS
  • JANSSEN GLOBAL SERVICES LLC
  • LEE BIOSOLUTIONS INC.
  • MERCK MILLIPORE
  • MESO SCALE DIAGNOSTICS, LLC
  • PERKINELMER INC.
  • QUEST DIAGNOSTICS
  • SIGNOSIS INC.
目錄
Product Code: BIO184A

Report Highlights:

The global market for tumor-specific antigen should grow from $1.8 billion in 2018 to $2.4 billion by 2023 at a compound annual growth rate (CAGR) of 6.2% for the period of 2018-2023.

Non-Coding region market for tumor-specific antigen should grow from $1.2 billion in 2018 to reach $1.7 billion by 2023 at a CAGR of 6.4% for the period of 2018-2023.

Coding region market for tumor-specific antigen should grow from $589.6 million in 2018 to reach $777.8 million by 2023 at a CAGR of 5.7% for the period of 2018-2023.

Report Scope:

The scope of this report is broad and covers category, source and applications of Tumor-specific Antigen. The market has been segmented by source into coding region and Non-Coding region. Revenue forecasts from 2017 to 2023 are given for each segment and regional market with estimated value derived from the revenue of manufacturers.

The report also includes a discussion of the major players across each region of the Tumor-specific antigen market. Further, it explains the major drivers and regional dynamics of the global Tumor-specific antigen market and current trends within the industry.

The report concludes with a special focus on vendor landscape and includes detailed profiles of the main vendors in the Tumor-specific antigen market.

Report Includes:

  • 75 data tables and 61 additional tables
  • An overview of the global market for tumor-specific antigen
  • Analyses of global market trends, with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Coverage of various types of product available in the tumor-specific antigen market and discussion of their potential applications
  • Information on oncofetal, oncoviral, overexpressed/accumulated, mutated, lineage restricted and idiotypic tumor-specific antigens and discussion of their specific targets
  • Insights into regulatory framework and policies and funding initiatives by the government for cancer research
  • A look into advancements in antigen specific T-Cell therapy for cancer and innovation within the industry
  • Detailed profiles of the major vendors in the global tumor-specific antigen market including Agilent Technologies Inc., AIVITA Biomedical, Eli Lilly and Co., GO Therapeutics and Merck Millipore

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Market Overview
  • Market Potential
  • Investment Analysis
  • Regulatory Framework
    • United States
    • European Union
    • Australia
    • Japan
    • India
    • China
  • Industry Growth Drivers
    • Surging Demand for Potential Cancer Biomarker Candidates
    • Rising Prevalence of Cancer
    • Increasing Investments in Cancer Diagnosis and Research
    • Rising Focus on Developing Targeted Therapies
    • Antigen Specific T-Cell Therapy

Chapter 4: Tumor-specific Antigen Market by Category

  • Oncofetal
  • Oncoviral
  • Overexpressed/Accumulated
  • CT9/CT10
  • Mutated
  • Lineage-Restricted Antigen
  • Idiotypic
  • Others

Chapter 5: Tumor-specific Antigen Market by Source

  • Coding Region
  • Non-Coding Region
    • Growing the Background of Immunotherapy Targets

Chapter 6: Tumor-specific Antigen Market by Application

  • Diagnostics
  • Drug Discovery and Development
  • Therapeutics
  • Risk Assessment
  • Prognostics
  • Clinical and Basic Research

Chapter 7: Tumor-specific Antigen Market by Region

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • France
    • Germany
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East and Africa

Chapter 8: Tumor-specific Antigen Market Industry Structure

  • Industry Structure
    • Procurement of Raw Materials
    • Manufacturing/Development Process
    • End-Users
  • Innovation in the Market
  • Competitive Analysis

Chapter 9: Company Profiles

  • ABCAM PLC
  • AGILENT TECHNOLOGIES INC.
  • AIVITA BIOMEDICAL
  • BBI GROUP
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES INC.
  • BRIGHTPATH BIOTHERAPEUTICS
  • CARIS LIFE SCIENCES INC.
  • CISBIO BIOASSAYS
  • CREATIVE DIAGNOSTICS
  • ELI LILLY AND CO.
  • ENZO BIOCHEM INC.
  • EXTERNAUTICS
  • F. HOFFMANN-LA ROCHE LTD.
  • GO THERAPEUTICS
  • JANSSEN GLOBAL SERVICES LLC
  • LEE BIOSOLUTIONS INC.
  • MERCK MILLIPORE
  • MESO SCALE DIAGNOSTICS, LLC
  • PERKINELMER INC.
  • QUEST DIAGNOSTICS
  • SIGNOSIS INC.

List of Tables

  • Summary Table: Global Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 1: Investment Analysis
    • Table 2: Biomarkers for Cancer Detection, Diagnosis and Prognosis
    • Table 3: Protein Arrays: Cancer Biomarker Discovery
    • Table 4: Global Prevalence of Cancer, by Type, 2016
    • Table 5: Regional Cancer Prevalence, by Type, 2015 and 2016
    • Table 6: Investment in Cancer, by Area of Research, 2017
    • Table 7: Investments in Cancer-Based Research, 2016-2018
    • Table 8: Molecular Targeted Therapy in Anticancer
    • Table 9: CAR Target Antigen for Hematologic Malignancies and Potential Off-Tumor Targets
    • Table 10: Global Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 11: Tumor Antigen
    • Table 12: Global Market for Oncofetal Antigen, by Region, Through 2023
    • Table 13: Pharmaceutical and Bioinformatic Partnerships and Alliances
    • Table 14: Global Market for Oncoviral Antigen, by Region, Through 2023
    • Table 15: U.S. R&D Funding for Basic Research
    • Table 16: Global Market for Overexpressed/Accumulated Antigen, by Region, Through 2023
    • Table 17: Investment in Cancer, by Research Area
    • Table 18: Global Market for CT9/CT10 Antigen, by Region, Through 2023
    • Table 19: Regional Cancer Prevalence, by Type, 2015 and 2016
    • Table 20: Global Market for Mutated Antigen, by Region, Through 2023
    • Table 21: Global Leukemia Deaths, 2016
    • Table 22: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
    • Table 23: Global Market for Lineage Restricted Antigen, by Region, Through 2023
    • Table 24: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
    • Table 25: Global Prevalence of Cancer, by Type, 2016
    • Table 26: Global Cancer Mortalities, by Type, 2016
    • Table 27: Global Market for Idiotypic-Based Antigen, by Region, Through 2023
    • Table 28: Clinical Trials in Idiotypic
    • Table 29: Identified Post-Translationally Modified AutoAntigen
    • Table 30: Global Market for Other Antigen, by Region, Through 2023
    • Table 31: Global Prevalence of Diabetes, 2017 and 2045
    • Table 32: Global Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 33: Tumor and Tissue-Specific Promoters Used to Generate Tumor-specific Antigen Sourced Through Coding Region
    • Table 34: Global Market for Coding Region-Based Antigen, by Region, Through 2023
    • Table 35: Global Market for Non-Coding Region-Based Antigen, by Region, Through 2023
    • Table 36: Global Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 37: Key Immunological Techniques for Diagnosis of Cancer
    • Table 38: Global Market for Tumor-specific Antigen in Diagnostic Applications, by Region, Through 2023
    • Table 39: Circulating Antigen and Immunodiagnosis of Cancer
    • Table 40: Global Market for Tumor-specific Antigen in Drug Discovery and Development Applications, by Region, Through 2023
    • Table 41: Clinical Trials Involving Tumor-specific Antigen for Cancer Therapeutics
    • Table 42: Global Market for Tumor-specific Antigen in Therapeutic Applications, by Region, Through 2023
    • Table 43: Global Market for Tumor-specific Antigen in Risk Assessment Applications, by Region, Through 2023
    • Table 44: Global Market for Tumor-specific Antigen in Prognostic Applications, by Region, Through 2023
    • Table 45: Global Prevalence of Different Cancers, by Country, 2016
    • Table 46: Deaths from Different Cancer Type, by Country, 2016
    • Table 47: NCI Funding, 2012-2017
    • Table 48: Global Market for Tumor-specific Antigen in Clinical and Basic Research Applications, by Region, Through 2023
    • Table 49: North American Market for Tumor-specific Antigen, by Country, Through 2023
    • Table 50: North American Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 51: U.S. Funding for Cancer Research, by Type, 2015 and 2016
    • Table 52: North American Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 53: U.S. Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 54: Canadian Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 55: North American Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 56: European Market for Tumor-specific Antigen, by Country/Region, Through 2023
    • Table 57: European Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 58: Cancer Prevalence in the U.K., by Country, 2015 and 2020
    • Table 59: European Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 60: U.K. Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 61: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
    • Table 62: French Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 63: German Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 64: Ongoing Cancer-Based Trials in Germany
    • Table 65: Cancer Cases in Spain, 2012 and 2015
    • Table 66: European Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 67: Spanish Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 68: Projects Recommended to the NCU Board for Funding, 2016
    • Table 69: Rest of European Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 70: Asia-Pacific Market for Tumor-specific Antigen, by Country/Region, Through 2023
    • Table 71: Asia-Pacific Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 72: Cancer Incidence in China, 2016
    • Table 73: Asia-Pacific Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 74: Chinese Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 75: Clinical Trials for Cancer
    • Table 76: Indian Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 77: Asia-Pacific Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 78: Japanese Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 79: Australian Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 80: Change in Cancer Prevalence in Other APAC Countries, 2005-2016
    • Table 81: Rest of APAC Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 82: Clinical Trials for Tumor-specific Antigen: Singapore
    • Table 83: RoW Market for Tumor-specific Antigen, by Region, Through 2023
    • Table 84: Cancer Incidence in Brazil, 2016
    • Table 85: Latin American Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 86: RoW Market for Tumor-specific Antigen, by Category, Through 2023
    • Table 87: Causes of Death in Argentina and Percentage Change, 2005-2016
    • Table 88: RoW Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 89: RoW Market for Tumor-specific Antigen, by Application, Through 2023
    • Table 90: Cancer Prevalence in Kenya, by Type, 2015 and 2016
    • Table 91: Middle Eastern and African Market for Tumor-specific Antigen, by Source, Through 2023
    • Table 92: Global Suppliers of Tumor-specific Antigen Market
    • Table 93: Selected Tumor-specific Antigen Companies
    • Table 94: Cancer Antigen for Clinical Trials, as of January 2019
    • Table 95: Product Launches, Product Development and FDA Clearance
    • Table 96: Notable Mergers and Acquisitions
    • Table 97: Notable Agreements, Collaborations and Partnerships
    • Table 98: Notable Funding, Expansion and Divestment
    • Table 99: Abcam PLC: Product Portfolio
    • Table 100: Abcam PLC: Recent Developments
    • Table 101: Agilent Technologies Inc.: Product Portfolio
    • Table 102: Agilent Technologies Inc.: Recent Developments
    • Table 103: AIVITA Biomedical: Product Portfolio
    • Table 104: AIVITA Biomedical: Recent Developments
    • Table 105: BBI Group: Product Portfolio
    • Table 106: Biomerieux SA: Product Portfolio
    • Table 107: Bio-Rad Laboratories Inc.: Product Portfolio
    • Table 108: Bio-Rad Laboratories Inc.: Recent Developments
    • Table 109: BrightPath Biotherapeutics: Product Portfolio
    • Table 110: BrightPath Biotherapeutics: Recent Developments
    • Table 111: Caris Life Sciences Inc.: Product Portfolio
    • Table 112: Caris Life Sciences Inc.: Recent Developments
    • Table 113: Cisbio Bioassays: Product Portfolio
    • Table 114: Creative Diagnostics: Product Portfolio
    • Table 115: Creative Diagnostics: Recent Developments
    • Table 116: Eli Lilly and Co.: Product Portfolio
    • Table 117: Eli Lilly and Co.: Recent Developments
    • Table 118: Enzo Biochem Inc.: Product Portfolio
    • Table 119: Enzo Biochem Inc.: Recent Developments
    • Table 120: Externautics: Product Portfolio
    • Table 121: F. Hoffmann-La Roche Ltd.: Product Portfolio
    • Table 122: F. Hoffmann-La Roche Ltd.: Recent Developments
    • Table 123: GO Therapeutics: Product Portfolio
    • Table 124: GO Therapeutics: Recent Developments
    • Table 125: Janssen Global Services LLC: Product Portfolio
    • Table 126: Janssen Global Services LLC: Recent Developments
    • Table 127: Lee Biosolutions Inc.: Product Portfolio
    • Table 128: Merck Millipore: Product Portfolio
    • Table 129: Merck Millipore: Recent Developments
    • Table 130: Meso Scale Diagnostics, LLC: Product Portfolio
    • Table 131: Meso Scale Diagnostics, LLC: Recent Developments
    • Table 132: PerkinElmer Inc.: Product Portfolio
    • Table 133: PerkinElmer Inc.: Recent Developments
    • Table 134: Quest Diagnostics: Product Portfolio
    • Table 135: Quest Diagnostics: Recent Developments
    • Table 136: Signosis Inc.: Product Portfolio

List of Figures

  • Summary Figure: Global Market for Tumor-specific Antigen, by Source, 2017-2023
    • Figure 1: Regional Prevalence of Cancer, 2015-2016
    • Figure 2: Global Prevalence of Cancer, by Type, 2016
    • Figure 3: Targeting of Tumor-specific Mutated Antigen in T-Cell Immunotherapy
    • Figure 4: Global Leukemia Deaths, 2016
    • Figure 5: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
    • Figure 6: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
    • Figure 7: Global Prevalence of Cancer, by Type, 2016
    • Figure 8: Global Cancer Mortalities, by Type, 2016
    • Figure 9: Determination of Antibody Idiotype
    • Figure 10: Global Prevalence of Diabetes, 2017 and 2045
    • Figure 11: Sources of Tumor-specific Antigen
    • Figure 12: Key Applications: Tumor-specific Antigen
    • Figure 13: Drug Discovery Cycle
    • Figure 14: Clinical Cancer Research for Therapeutic Applications
    • Figure 15: The Role of Prognostic and Predictive Markers in Individualized Treatment
    • Figure 16: Global Prevalence of Different Cancers, by Country, 2016
    • Figure 17: Deaths from Different Cancer Type, by Country, 2016
    • Figure 18: NCI Funding, 2012-2017
    • Figure 19: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
    • Figure 20: Cancer Incidence in China, 2016
    • Figure 21: Major Breakthroughs in Cancer Research: India
    • Figure 22: Cancer Prevalence in Kenya, by Type, 2015 and 2016
    • Figure 23: Tumor-specific Antigen Industry Structure
    • Figure 24: Tumor-specific Antigen Development Flow Chart